First discovered by Friedenstein in 1976, mesenchymal stem cells (MSCs) are adult stem
cells found throughout the body that share a fixed set of characteristics. Discovered initially …

Despite improvements in modern cardiovascular therapy, the morbidity and mortality of
ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and …

Cardiovascular disease is a leading cause of death worldwide. The limited capability of
heart tissue to regenerate has prompted methodological developments for creating de novo …

BACKGROUND Decades of laboratory and clinical investigation have led to successful
therapies using hematopoietic stem cells (HSCs), but few other cell therapies have …

Although cellular therapies hold great promise for the treatment of human disease, results
from several initial clinical trials have not shown a level of efficacy required for their use as a …

The strategy of using mesenchymal stem cells (MSCs) as a living carrier for active delivery of
therapeutic agents targeting tumor sites has been attempted in a wide range of studies to …

Human pluripotent stem cell-derived cardiomyocytes (CMs) are a promising tool for cardiac
cell therapy. Although transplantation of induced pluripotent stem cell (iPSC)-derived CMs …

In regenerative medicine, clinical imaging is indispensable for characterizing damaged
tissue and for measuring the safety and efficacy of therapy. However, the ability to track the …

Stem cell therapies are increasingly recognized as the future direction of regenerative
medicine, but the biological fate of the administrated stem cells remains a major concern for …

Background Myocardial ischemia–reperfusion injury (MIRI) is a major obstacle in the
treatment of ischemic heart disease. Recent studies have shown that exosomes—small …